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Development and validation of a fluorescent 
microsphere immunoassay for anti-IgA
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Anti-IgA may cause anaphylactic transfusion reactions in IgA-
deficient individuals. Testing for IgG anti-IgA is useful to identify 
persons at risk. This report describes an immunoassay for anti-
IgA that uses polyclonal IgA coupled to fluorescent microspheres 
as an immunosorbent. Anti-IgA is detected by phycoerythrin- 
labeled anti-IgG. The assay is calibrated in arbitrary units by use 
of a serum that contains anti-IgA. Dose-response studies with sera 
that contain anti-IgA showed positive responses at dilutions up to 
32-fold greater than the dilution used to test patients’ samples. 
Inhibition studies with purified IgA and IgA-deficient serum 
showed no inhibition with IgA-deficient serum and complete inhi-
bition with soluble IgA. Clinical tests performed in more than 90 
assays had a CV of 13.6 percent for measurements of an internal 
positive control. The fluorescent immunoassay method is rapid, 
reproducible, and sensitive to low concentrations of IgG anti-IgA. 
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Selective IgA deficiency is the most common humoral immunodeficiency.1,2 The reported frequency varies widely in different populations. The frequency of IgA 
deficiency in Caucasians of Northern European ancestry is 
estimated to be approximately 1 in 600 with lesser frequen-
cies reported in Asian populations.2 The definition of IgA 
deficiency is determined in part by the analytic sensitivity 
of immunoassay methods used to measure IgA. Commonly 
used nephelometric immunoassays are capable of detect-
ing IgA at concentrations greater than 0.3 mg/dL, and 0.5 
mg/dL is often cited as a cutoff concentration to define 
IgA deficiency in adults. A lower concentration, 0.05 mg/
dL, is used to define IgA-deficient blood donors and blood 
products.3–5 Approximately one third of persons with IgA 
deficiency have detectable anti-IgA.2,6 The mechanisms re-
sponsible for development of anti-IgA in IgA-deficient indi-
viduals are unknown.
Anti-IgA has been reported to be associated with severe 
anaphylactic transfusion reactions in IgA-deficient patients, 
and antibodies of both the IgG and IgE isotypes have been 
described.6–8 Although it is assumed that IgE antibodies 
may be capable of eliciting anaphylactic transfusion reac-
tions, not all investigators have been able to identify such 
antibodies, and the mechanism(s) by which anti-IgA pro-
duces anaphylactic reactions remains unclear. Although 
several studies suggest that IgG anti-IgA is associated with 
transfusion reactions, reported data also indicate that some 
patients with anti-IgA fail to react to IgA and reactions have 
been described in patients who have no demonstrable anti-
bodies.9–11 Nevertheless, accurate identification of IgA- 
deficient persons with anti-IgA is important to investigate 
the possible etiology of immediate hypersensitivity trans-
fusion reactions and to facilitate the optimal use of blood 
products obtained from IgA-deficient donors.
A variety of analytical methods have been used to detect 
anti-IgA, including double immunodiffusion with purified 
IgA paraproteins, hemagglutination, two-site immunomet-
ric assays, flow cytometric immunoassays, and enzyme im-
munoassays.12–17 In this report we describe the development, 
analytical validation, and clinical performance of a fluores-
cent microsphere immunoassay for IgG anti-IgA. The assay 
has excellent analytic sensitivity and reproducibility and 
a rapid turnaround time, and makes use of commercially 
available reagents and instrumentation.
Materials and Methods
Institutional Review Board approval was obtained for 
use of residual patients’ sera and to review the medical rec-
ords of all patients tested as part of this study. Previously 
tested sera (n = 7) shown to contain IgG anti-IgA were avail-
able from the Division of Transfusion Medicine.15 These sera 
were from healthy blood donors who had fulfilled all dona-
tion criteria defined by the U.S. Food and Drug Adminis-
tration and who had been found to be negative on blood 
donor infectious disease testing. The donors were identified 
by a routine screening process used in our collection center 
to identify IgA-deficient donors as previously described.18 
None of the seven donors had previously been transfused, 
and therefore none had a clinical history of anaphylaxis to 
IgA. All represented selective IgA deficiency with anti-IgA. 
Serum from a patient with IgA deficiency, a history of pre-
vious anaphylactic transfusion reactions, and high levels of 
IgG anti-IgA was tested at serial dilutions (described later) 
and was used as the assay calibrator (1 in 1280 dilution) 
and internal control (1 in 640 dilution) in all subsequent 
assays. Serum samples from 133 healthy adults were tested 
to determine background binding of IgG to the IgA-coupled 
fluorescent microspheres (described later), and specimens 
submitted for testing in the clinical laboratory obtained 
from 724 patients suspected of having immediate hyper-
sensitivity transfusion reactions were used to determine 
the frequency of IgG anti-IgA in patients. Additional clini-
cal information for the 724 patients, beyond the fact that 
they were suspected of having an immediate hypersensitivity 
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reaction to transfusion, was not available. The IgA status 
of the 133 healthy subject and 724 patient samples was 
determined by nephelometry using a Dade Behring BN II 
Nephelometer (Siemens Healthcare Diagnostics, Deerfield, 
IL) and Dade Behring IgA reagents according to manufac-
turer’s instructions.
Preparation of IgA-Coupled Fluorescent Microspheres
Purified, human polyclonal IgA (Fitzgerald Industries 
International Inc., Concord, MA) was coupled covalently 
to fluorescent microspheres (SeroMap D microspheres, 
Luminex Corp., Austin, TX) by a modified carbodiimide 
method as follows19: An aliquot of 50 × 106 microspheres 
was reacted in the dark for 20 minutes with 100 μL of 50 
mg/mL N-hydroxysulfosuccinimide and 100 μL of 50 mg/
mL 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in a 
final volume of 1 mL of 100 mM monobasic sodium phos-
phate, pH 6.2. After activation, the microspheres were 
washed twice with 50 mM MES, pH 5.0 (2-[N-morpholino] 
ethanesulfonic acid), and 1 mg of purified IgA in 1.5 mL of 
MES, pH 5.0, was added. The microspheres were then in-
cubated in the dark for 2 hours at room temperature. The 
IgA-coupled microspheres were washed, resuspended in 
0.1 M PBS with 0.05% Tween 20, and incubated in the dark 
for an additional 30 minutes. After this incubation, the 
IgA-coupled microspheres were diluted 1 in 1600 in PBS 
with 1% BSA, 10% sodium azide, and 100 μL/L of protease 
inhibitor cocktail #P2714 (Sigma Chemical Co., St. Louis, 
MO) to a final concentration of 31,350 microspheres/mL.
Dose-Response and Dose-Inhibition Analyses of IgA-
Coupled Fluorescent Microspheres
Maximum specific binding of IgG antibodies to the 
IgA-coupled microspheres was tested in a standard assay 
(described later) by incubating 100-μL aliquots of diluted 
microspheres with decreasing serial twofold dilutions (1 in 
20 through 1 in 81,920) of positive serum. The specificity of 
binding of IgG to the IgA-coupled microspheres was tested 
in inhibition assays with purified polyclonal IgA (Fitzger-
ald Industries International Inc.) and IgA-deficient serum 
inhibitors. Aliquots of diluted, purified IgA or diluted, IgA-
deficient serum (100 μL in PBS with 1% BSA diluent) were 
incubated overnight with an equal volume of diluted (1 
in 40) positive serum. The incubated mixtures were then 
tested in a standard assay, and inhibition by purified IgA or 
IgA-deficient serum was calculated by comparing the fluo-
rescent responses of the incubated mixtures to results for 
the uninhibited positive serum. Nonspecific binding of IgG 
protein to the IgA-coupled microspheres was determined 
by testing sera from healthy adults in standard assays. A 
limit of inhibition was not chosen as inhibition is dose de-
pendent (see Results section).
Standard Assay Format
Tests for IgG anti-IgA were performed in filter micro-
titer plates (MABV N1250, Millipore Inc., Billerica, MA) as 
follows: 100 μL of the positive calibrator, internal control, 
or test sera diluted 1 in 40 in PBS with 1% BSA was incubat-
ed with 100 μL of IgA-coupled microspheres in darkened, 
covered microtiter plates for 30 minutes at room tempera-
ture. After incubation, the microspheres were washed five 
times with 1% BSA in PBS, then 100 μL of diluted, R- 
phycoerythrin conjugated, goat anti-human IgG (Jackson 
ImmunoResearch, West Grove, PA) was added to each well, 
and the plates were again incubated in the dark for 1 hour at 
room temperature. Binding of IgG antibodies to the micro-
spheres was measured using a Luminex 100 platform (Lu-
minex Corp.) according to the manufacturer’s instructions. 
Results were calculated by STATLia version 3.2 (Brendan 
Scientific, Carlsbad, CA). The raw fluorescent scores for the 
calibrator and internal control in fluorescent response units 
(FRU) were assigned arbitrary values of 100 and 200 units 
(U), respectively, and results for patients’ sera were calcu-
lated by comparison to the calibrator as follows: Test result 
(U) = FRU patient / FRU calibrator × 100. Results greater
than 200 U and less than 100 U were reported as positive
and negative, respectively. Results between 100 and 200 U
were reported as equivocal. Inhibition studies with soluble
IgA were not performed on routine clinical specimens that
gave positive or equivocal results.
Results
 Specific binding of IgG antibodies to the IgA-coupled 
microspheres was determined by testing serial twofold 
dilutions of known positive sera. Results of a typical 
dose-response analysis for one strongly positive serum are 
shown in Figure 1. The maximum response for this serum 
exceeded 20,000 arbitrary FRU at a 1 in 40 dilution (Fig. 
2). This particular positive serum was chosen as a calibrator 
and internal control for all subsequent assays. The serum 
was used as a calibrator at a 1 in 1280 dilution (100 U, de-
scribed earlier) and as an internal control at a 1 in 640 dilu-
tion (200 U, previously described).
Nonspecific binding of IgG to the IgA-coupled micro-
spheres was determined by testing sera from 133 healthy, 
non–IgA-deficient adults. The results are shown in Figure 
2 for tests performed on serial twofold dilutions of sera 
from 1 in 20 to 1 in 80. The mean, standard deviation, and 
maximum response for sera in the normal group displayed 
in Figure 2 were 984, 819, and 5884 FRU, respectively. All 
but five sera from these healthy adults had fewer than 3000 
FRU at a 1 in 40 dilution. The upper limit of nonspecific 
binding in the fluorescent microsphere immunoassay (5079 
FRU) was calculated as the mean plus five standard devia-
tions for tests of normal sera at a 1 in 40 dilution using the 
standard assay format. This level of binding corresponded 
approximately to the response of the positive serum cali-
brator (4206 FRU), which was assigned an arbitrary value 
of 100 U. The 100-U value for the assay calibrator obtained 
by testing this serum at a 1 in 1280 dilution represents a 32-
fold greater dilution of the positive serum calibrator than 
is used routinely to test patients’ specimens. The cutoff for 
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 Since this immunoassay was  approved for routine use 
in the clinical laboratory, we have performed more than 90 
assay runs for IgG anti-IgA on 724 persons during a period 
of approximately 18 months using two different lots of IgA-
coupled microspheres. Interassay reproducibility across all 
90 assay runs as measured by the CV of replicate measure-
ments of the internal control was 13.6 percent (data not 
shown). Tests performed on sera from these 724 persons 
yielded 46 results greater than 100 U (6.3%). In this group, 
38 sera had results greater than 200 U, and 8 sera yielded 
equivocal results. The medical histories of four patients 
seen at this institution who had anaphylactic reactions and 
results greater than 200 U were available for review: all had 
IgA deficiency as revealed by serum IgA levels of less than 
0.5 mg/dL.
Discussion
 The fluorescent microsphere immunoassay described 
in this report compares favorably with several previously 
reported methods for detecting anti-IgA.12–17 The assay 
method has excellent analytical sensitivity as revealed by 
dose-response studies with positive sera and inhibition 
studies with soluble IgA. In addition, the results show ex-
cellent discrimination between nonspecific binding and 
binding produced by IgG anti-IgA. Only slightly more than 
1 percent of sera tested in the clinical laboratory with this 
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Fig. 2. Determination of nonspecific binding of sera from healthy adults. 
Fluorescent responses for sera from healthy adults tested at serial twofold 
dilutions are plotted and can be compared with the positive serum used as 
the assay calibrator (top line). One serum from a healthy control produced 
binding intermediate to the positive serum and the majority of other sera from 
healthy adults (see text).
defining a positive result was established at 200 U (a 1 in 
640 dilution of the positive serum, 7165 FRU) to avoid mis-
classifying any patients’ sera as positive that did not contain 
IgG anti-IgA. Results between 100 and 200 U were classified 
as equivocal. In this classification, serum from one healthy 
adult shown in Figure 2 would be classified as equivocal, 
and no sera would be classified as positive.
 The specificity of binding of IgG antibodies to the IgA-
coupled microspheres was determined by testing a number 
of positive sera in sequential dose-inhibition assays with 
purified polyclonal IgA and IgA-deficient serum inhibitors 
(Fig. 3). Excess polyclonal IgA abolished binding of IgG anti-
bodies in all positive sera, but IgA-deficient serum had no 
effect on binding of IgG antibodies. Significant inhibition of 
binding of IgG antibodies to the IgA-coupled microspheres 
(up to 40%) was produced by adding as little as 1 ng of puri-
fied polyclonal IgA as an inhibitor.
Fig. 3. Inhibition studies with polyclonal IgA and IgA-deficient serum 
inhibitors. Sera from seven patients with IgG anti-IgA were tested. 
Fluorescent responses are plotted versus the log IgA inhibitor in nanograms 
per milliliter (upper frame) or dose of IgA-deficient serum inhibitor (lower 
frame; see text).
Fig 1. Dose-response analysis of a positive serum used as assay calibrator 
and internal control. Fluorescent response units are plotted versus dilutions 
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assay yielded equivocal results during more than 18 months 
of use, and those positive sera, obtained from four patients 
whose medical histories were available for review, were 
confirmed as being associated with immediate hypersensi-
tivity transfusion reactions and IgA deficiency.
Overall, the frequency of positive test results among the 
724 patient samples tested during 18 months of use was 5.2 
percent. In the paper published by Sandler et al.,11 anti-IgA 
was detected in 18 percent of sera submitted for testing. 
How can this discrepancy with our results be explained? 
The frequency of positive results is determined primarily by 
the selectivity of physicians in choosing sera for testing. It 
is worth noting that our institution accepts specimens from 
laboratories around the world for testing, and it must be as-
sumed that not all requests are supported by strong clinical 
evidence of prior transfusion reactions or even diminished 
levels of IgA in blood. Therefore, no direct comparison can 
be made with the experience reported by Sandler et al.11
The initial methods for detecting anti-IgA described 
in the medical literature used an immunodiffusion tech-
nique that was sensitive to microgram per milliliter con-
centrations of antibodies, required purified IgA myeloma 
proteins as reagents, and took several days to generate 
test results.12,20 Subsequent generations of immunoassays, 
which included hemagglutination assays, modified radio-
immunoassays, and sandwich immunoradiometric assay 
methods, had improved analytical sensitivity and were ca-
pable of detecting nanogram per milliliter concentrations 
of anti-IgA.11,15 Despite having improved analytical sensitiv-
ity, these methods also used purified IgA myeloma proteins 
as reagents. The radioassay methods took days to perform 
and had the added disadvantage of using radionuclides in 
the assay procedures, which limited the shelf life of test re-
agents and required monitoring of testing personnel and 
disposal of radioactive wastes. Hemagglutination assays 
were more rapid, but had high levels of interassay variabil-
ity and generated occasional false-negative results attribut-
able to prozone phenomena. Sandwich immunoradiometric 
assays could be adapted to the use of purified polyclonal IgA 
as an antigen source, but these methods still required the 
use and disposal of radionuclides. More recently, enzyme 
immunoassay, flow cytometric immunoassay, and particle 
gel immunoassay methods have been used to measure anti-
IgA.13,14,16 Compared with enzyme immunoassay, the flow 
cytometric assay is reported to be more reproducible as 
large numbers of latex microbeads are used to test each in-
dividual serum specimen compared with one or two wells in 
a typical microtiter enzyme immunoassay. The fluorescent 
microsphere immunoassay we have developed is similar in 
design to a flow cytometric immunoassay. Both assays rely 
on optical measurement of fluorescence generated by the 
binding of fluorochrome-conjugated anti-IgG to specific 
antibodies bound to IgA-coupled beads. In the fluorescent 
microsphere immunoassay, IgA is coupled covalently to 
fluorescent microspheres. Covalent coupling of IgA to the 
microsphere immunosorbent reagent contributes to a long 
shelf life and very low nonspecific binding. We have noted 
stable binding of calibrator and control sera to the IgA-
coupled microspheres for several months of use. In other 
respects, the fluorescent microsphere and flow cytometric 
assays appear quite comparable, although it is not possible 
to compare the analytic sensitivity of these methods with-
out performing tests on the same sera.
As noted earlier, the fluorescent microsphere immuno-
assay for IgG anti-IgA we developed has proved reliable for 
more than 18 months of routine use in the clinical labora-
tory. Compared with the immunoradiometric assay we used 
for several years, the fluorescent microsphere immuno-
assay has improved our practice by markedly reducing the 
time required to evaluate patients who might be at risk of 
anaphylactic transfusion reactions or might require blood 
products free of IgA. The results of the microsphere immu-
noassay are available within 4 hours, whereas those of the 
immunoradiometric assay require 48 hours to be available. 
This has the potential to decrease utilization of the rare IgA-
deficient plasma product inventory maintained at our insti-
tution.
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